Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors
|Glossary of Terms for Supplement|
Carcinogenic = producing or tending to produce cancer
Genotoxic = damaging to genetic material such as DNA and chromosomes
Mutagenic = inducing or capable of inducing genetic mutation
Teratogenic = interfering with fetal development and resulting in birth defects
Data are available from clinical trials in human pregnancy for the nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine, abacavir, lamivudine, didanosine, emtricitabine, and stavudine and the nucleotide NRTI tenofovir disoproxil fumarate (TDF). The nucleoside analogue drugs require three intracellular phosphorylation steps to form the triphosphate nucleoside, which is the active drug moiety. TDF, an acyclic nucleotide analogue drug, contains a monophosphate component attached to the adenine base and, hence, requires only two phosphorylation steps to form the active moiety.
For information regarding the nucleoside analogue drug class and potential mitochondrial toxicity in pregnancy and to the infant, see the Recommendations for Use of Antiretroviral Drugs During Pregnancy and Long-Term Follow-Up of Antiretroviral Drug-Exposed Infants.
Abacavir (Ziagen, ABC)
Didanosine (Videx, ddI)
Emtricitabine (Emtriva, FTC)
Lamivudine (Epivir, 3TC)
Stavudine (Zerit, d4T)
Tenofovir alfenamide (Genvoya, Odefsey, Descovy, TAF)
Tenofovir disoproxil fumarate (Viread, TDF)
Zidovudine (Retrovir, AZT, ZDV)